NovoCure Ltd Director Timothy Scannell Retires from Board

What Happened

• NovoCure Ltd announced in an 8-K filed on September 9, 2026 that director Timothy Scannell retired from the Company’s Board and his seat was formally vacated effective September 2, 2026.
• The company stated Mr. Scannell’s retirement followed five years of service and did not result from any disagreement with NovoCure or its management.

Key Details

• Retirement effective date: September 2, 2026.
• Length of service: five years on the Board.
• Vacancy: seat was formally vacated pursuant to the Company’s Articles of Association.
• 8-K filing date and signature: filed September 9, 2026; signed by Christoph Brackmann, Chief Financial Officer.

Why It Matters

• Board composition and director turnover are governance matters investors watch; a director vacancy could affect committee membership or board votes until a replacement is named.
• The company’s statement that the retirement was not due to any disagreement reduces immediate governance-concern risk, but investors should watch for subsequent filings announcing a new director or changes to board committees.